Screener
Gyre Therapeutics, Inc. GYRE Income Tax
Income Tax at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Gyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncomeTaxExpenseBenefit.
The source filing: Gyre Therapeutics, Inc.’s 10-Q, filed August 7, 2026.
- Filed
- Aug 7, 2026, 5:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-340448
| Line item | Three Months Ended June 30, | Six Months Ended June 30, |
|---|---|---|
| Other expense, net | (488)) | (301)) |
| Change in fair value of warrant liability | 212 | 2,467 |
| (Loss) Income before income taxes | (1,575)) | 4,265) |
| Benefit (provision) for income taxes | (662) | (1,563)) |
| Net (loss) income | (2,237)) | 2,702) |
| Accretion of Cullgen redeemable convertible preferred stock | (2,642)) | (5,220)) |
| Net loss attributable to noncontrolling interest | (2,835)) | (2,644)) |
| Net (loss) income attributable to common stockholders | $$(2,044)) | $$126) |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Gyre Therapeutics, Inc.'s income tax?
- Gyre Therapeutics, Inc. (GYRE) reported income tax of -$164K in Q2 2026.
- How has Gyre Therapeutics, Inc.'s income tax changed year-over-year?
- Gyre Therapeutics, Inc.'s income tax decreased by 124.8% year-over-year, from $662K to -$164K.
- What is the long-term trend for Gyre Therapeutics, Inc.'s income tax?
- Over 3 years (2022 to 2025), Gyre Therapeutics, Inc.'s income tax has grown at a -3.7% compound annual growth rate (CAGR), from $5.1M to $4.56M.
- What does income tax mean?
- Total income tax expense (current + deferred) recognized in the income statement, representing the company's total tax obligation on pre-tax income.
Ask your AI about Gyre Therapeutics, Inc.'s income tax.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude